Pfizer
-
Pfizer expands AI drug discovery strategy through licensing agreement with Chai Discovery
Through this arrangement, Pfizer aims to accelerate the identification and design of new therapeutic candidates, particularly in areas where traditional research methods have faced limitations.
-
Pfizer secures US$10.5B Innovent Biologics alliance to scale its oncology pipeline
The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.
-
Pfizer obtains EC approval for first once-weekly subcutaneous hemophilia treatment
The approval applies to adolescents and adults weighing at least 35 kilograms who have haemophilia A with factor VIII inhibitors or haemophilia B with factor IX inhibitors.
-
Jamjoom Pharma expands manufacturing footprint with Pfizer’s facility acquisition in Saudi Arabia
The company expects the facility to increase production capacity and improve supply chain responsiveness across the Middle East and Africa (MEA).
-
Pfizer enters China’s weight-loss market as regulators approve the GLP-1 drug Xianweiying
Pfizer secured marketing rights to the GLP-1 compound ecnoglutide through a partnership with Hangzhou-based Sciwind Biosciences announced last month.
-
Pfizer signs USD530M agreement with Novavax for Matrix-M vaccine adjuvant technology
Pfizer will assume complete responsibility for developing and bringing to market any vaccine products that utilize Matrix-M technology.
-
Pfizer Foundation expands regional cancer care with new USD10M grant
The program will also work to increase access to chemotherapy and provide essential emotional support services for patients navigating their cancer journey.
-
Pfizer strengthens obesity drug pipeline with USD2B licensing deal with YaoPharma
YaoPharma stands to earn as much as USD1.94 billion in additional milestone payments tied to development, regulatory, and commercial achievements.